Debiopharm International
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Debiopharm International sits in the top decile of US sponsors by registered trial count (#538 of 15,742 sponsors by registered trial count).
Debiopharm International: 30 sponsored US clinical trials, 5 recruiting.
Debiopharm International sponsors 30 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 16 completed. 7 of these trials are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hepatitis C, with 2 trials.
Top-decile sponsor footprint
Debiopharm International ranks in the top decile of sponsors by registered trial count (#538 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
30 total, page 1 of 1
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
NCT06930625
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
NCT06969430
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
NCT06395753
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
NCT05765812
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
NCT04855656
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)
NCT06129539
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
NCT05815160
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
NCT05109975
Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
NCT05147350
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
NCT05147272
Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143
NCT04122625
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
NCT03834220
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL
NCT02564744
Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery
NCT02726438
Study of Debio 1450 for Bacterial Skin Infections
NCT02426918
A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers
NCT02214433
A Single Dose Study of Debio 1450 in Healthy Subjects
NCT02162199
Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option
NCT02094443
Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects
NCT01975337
Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations
NCT01948297
Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
NCT01467882
Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C
NCT01500772
Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients
NCT02753699
Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1
NCT01446250
Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
NCT01860326
Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants
NCT01318694
Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
NCT01215643
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
NCT01183169
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
NCT01078649
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
NCT00537407
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 8 |
| Phase 3 | 7 |
What is open in the Debiopharm International pipeline
5 recruiting of 30 indexed (17% open); 16 completed (53%).
Phase mix: 7 late (III/IV) vs 23 early (I/II) (early-phase heavy).
Top condition: Hepatitis C (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Debiopharm International: open-pipeline peers nationwide
Peers matched on 30 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Debiopharm International sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 30 trials (± recruiting share)
- Biotronik · 30 trials · 3% recruiting
- Charles Drew University of Medicine and Science · 30 trials · 3% recruiting
- Chiesi Farmaceutici S.p.A. · 30 trials · 13% recruiting
- Exact Sciences Corporation · 30 trials · 10% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Debiopharm International page
30 registered trials is a research-attention snapshot, not an endorsement of Debiopharm International or any single study.
- 5 of Debiopharm International's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hepatitis C is the condition Debiopharm International studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hepatitis C trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Debiopharm International pipeline card: 30 registered trials from official public datasets.Report a data error.